Jean Fajadet

Summary

Publications

  1. ncbi request reprint Catheter-induced left main dissection: a treatment dilemma
    Niall T Mulvihill
    Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
    Catheter Cardiovasc Interv 59:214-6. 2003
  2. ncbi request reprint Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial
    Jean Fajadet
    Clinique Pasteur, 45, Avenue du Lombez, 31300 Toulouse, France
    Circulation 111:1040-4. 2005
  3. ncbi request reprint Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population
    Didier Tchetche
    Clinique Pasteur, Toulouse, France
    EuroIntervention 5:659-65. 2010
  4. doi request reprint Stent implantation in aorto-ostial lesions: long-term follow-up and predictors of outcome
    Andre Luz
    Clinique Pasteur, Toulouse, France
    EuroIntervention 7:1069-76. 2012
  5. doi request reprint Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative
    Didier Tchetche
    Clinique Pasteur, Toulouse, France
    Am Heart J 164:402-9. 2012
  6. ncbi request reprint Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial
    Jean Fajadet
    Clinique Pasteur, Toulouse, France
    Circulation 114:798-806. 2006
  7. doi request reprint Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study
    Jean Fajadet
    Clinique Pasteur, Toulouse, France
    EuroIntervention 6:562-7. 2010
  8. doi request reprint Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system
    Didier Tchetche
    Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France
    EuroIntervention 8:556-62. 2012
  9. ncbi request reprint Long-term follow-up of percutaneous coronary intervention of unprotected left main lesions with drug eluting stents: predictors of clinical outcome
    Andrea Pavei
    Clinique Pasteur, Toulouse, France
    EuroIntervention 4:457-63. 2009
  10. ncbi request reprint Percutaneous treatment of coronary subclavian steal syndrome
    Niall T Mulvihill
    Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
    J Invasive Cardiol 15:390-2. 2003

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Catheter-induced left main dissection: a treatment dilemma
    Niall T Mulvihill
    Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
    Catheter Cardiovasc Interv 59:214-6. 2003
    ..However, there are potential life threatening complications which can occasionally occur. We describe one such complication and detail the management and clinical outcome...
  2. ncbi request reprint Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial
    Jean Fajadet
    Clinique Pasteur, 45, Avenue du Lombez, 31300 Toulouse, France
    Circulation 111:1040-4. 2005
    ..This analysis examined whether these beneficial effects persist over the longer term...
  3. ncbi request reprint Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population
    Didier Tchetche
    Clinique Pasteur, Toulouse, France
    EuroIntervention 5:659-65. 2010
    ..We report 30-day data from a mixed population of patients treated with either Medtronic CoreValve (MCV) or Edwards SAPIEN (ES) valves...
  4. doi request reprint Stent implantation in aorto-ostial lesions: long-term follow-up and predictors of outcome
    Andre Luz
    Clinique Pasteur, Toulouse, France
    EuroIntervention 7:1069-76. 2012
    ..To compare the outcomes of drug-eluting (DES) vs. bare-metal (BMS) stents for stenting of native aorto-ostial lesions (AOL) and to identify predictors of major adverse cardio and cerebrovascular events (MACCE)...
  5. doi request reprint Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative
    Didier Tchetche
    Clinique Pasteur, Toulouse, France
    Am Heart J 164:402-9. 2012
    ..Little is known about the impact of bleeding and red blood cells transfusion (RBC) on the outcome post transcatheter aortic valve implantation (TAVI)...
  6. ncbi request reprint Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial
    Jean Fajadet
    Clinique Pasteur, Toulouse, France
    Circulation 114:798-806. 2006
    ..The use of the Endeavor stent might reduce restenosis and stent thrombosis at 9 months...
  7. doi request reprint Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study
    Jean Fajadet
    Clinique Pasteur, Toulouse, France
    EuroIntervention 6:562-7. 2010
    ....
  8. doi request reprint Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system
    Didier Tchetche
    Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France
    EuroIntervention 8:556-62. 2012
    ..The aims of this paper were to describe the potential impact of the Accutrak™ catheter on the accuracy of positioning a 26 or 29 mm CoreValve® across the aortic annulus and its impact on the need for a pacemaker...
  9. ncbi request reprint Long-term follow-up of percutaneous coronary intervention of unprotected left main lesions with drug eluting stents: predictors of clinical outcome
    Andrea Pavei
    Clinique Pasteur, Toulouse, France
    EuroIntervention 4:457-63. 2009
    ..To evaluate the long-term follow-up of drug-eluting stents (DES) in the treatment of unprotected left main coronary artery (ULMCA)...
  10. ncbi request reprint Percutaneous treatment of coronary subclavian steal syndrome
    Niall T Mulvihill
    Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
    J Invasive Cardiol 15:390-2. 2003
    ..This syndrome can be successfully treated percutaneously with excellent immediate and long-term results...
  11. doi request reprint Current management of left main coronary artery disease
    Jean Fajadet
    Clinique Pasteur, Toulouse, France
    Eur Heart J 33:36-50b. 2012
    ..Further randomized trials must be conducted to precise the indications of both techniques of revascularization in the treatment of LM disease...
  12. ncbi request reprint Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients
    Mohamed Loutfi
    Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
    Catheter Cardiovasc Interv 58:451-4. 2003
    ..Consequently, even if drug-eluting stent technology can eliminate restenosis, disease progression will continue to impact the clinical outcome of diabetic patients after PCI...
  13. ncbi request reprint Rapid sealing of coronary perforations using polytetrafluoroethylene-covered stents
    Niall T Mulvihill
    Unite De Cardiologie Interventionnelle, Clinique Pasteur, Toulouse, France
    Am J Cardiol 91:343-6. 2003
  14. ncbi request reprint A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    N Engl J Med 346:1773-80. 2002
    ..Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris...
  15. ncbi request reprint Triple vessel stenting for triple vessel coronary disease
    Beatriz Villegas
    Institut Cardiovasculaire Paris Sud, 6 avenue du Noyer Lambert, 91300, Massy, France
    J Invasive Cardiol 14:1-5. 2002
    ..this prospective study was performed to measure the percentage of patients eligible for elective multiple stenting of triple vessel coronary artery disease and to examine their short- and intermediate-term outcomes...
  16. ncbi request reprint Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial)
    Ryota Sakurai
    Center for Cardiovascular Technology, Stanford University Medical Center, Stanford, California, USA
    Am J Cardiol 100:818-23. 2007
    ..In conclusion, ZES showed evenly inhibited neointima with no apparent adverse vascular response in stented and reference segments at 8 months compared with BMS...
  17. ncbi request reprint Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial
    Marco Valgimigli
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 49:431-41. 2007
    ....
  18. ncbi request reprint Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients
    Anthony Gershlick
    University Hospitals of Leicester School of Medicine, Leicester, United Kingdom
    Am J Cardiol 100:45M-55M. 2007
    ....
  19. ncbi request reprint Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting
    Luisa Gregorini
    Experimental Surgery and Transplantation Institute, Ospedale Maggiore IRCCS, University of Milano, Italy
    Circulation 106:2901-7. 2002
    ..Coronary flow reserve (CFR) is not normalized shortly after coronary stenting. We hypothesized that alpha-adrenergic coronary vasoconstriction acts to limit CFR...
  20. ncbi request reprint [Prognosis after acute coronary syndrome. Lack of difference according to the sex]
    Jean Paul Bounhoure
    Faculté de Médecine de Toulouse Rangueil, Universite Paul Sabatier, 1, avenue Jean Poulhes Toulouse 31403
    Bull Acad Natl Med 188:383-97; discussion 397-9. 2004
    ..Women with ACS who are at high risk derive the same benefit as men from early angioplasty and coronary stenting of the culprit lesion, with satisfactory in-hospital and mid-term outcomes...
  21. ncbi request reprint High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial
    Eberhard Grube
    J Am Coll Cardiol 44:1368-72. 2004
    ..Santa Clara, California/Boston Scientific Corp., Natick, Massachusetts) versus uncoated control stents (n = 140) in focal, de novo coronary lesions...